Trial reportExperimental and clinical psychopharmacology2013
Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Trial report in Experimental and clinical psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review.Frontiers in psychiatry · 2019Pooled it
- Pharmacological therapies for management of opium withdrawal.The Cochrane database of systematic reviews · 2018Pooled it
- Buprenorphine for managing opioid withdrawal.The Cochrane database of systematic reviews · 2017Pooled it
- Exploratory study of heart rate variability among participants with opioid use disorder inducted on gabapentin versus placebo during outpatient buprenorphine-assisted transition to injection naltrexone.Experimental and clinical psychopharmacology · 2025Trial
- Gabapentin and D-cycloserine alone and in combination with naloxone in methadone-maintained humans responding under a naloxone novel-response discrimination procedure.Behavioural pharmacology · 2025Trial
- Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone.The American journal of drug and alcohol abuse · 2025Trial
- Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder.Pharmacology, biochemistry, and behavior · 2022Trial
- Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial.JAMA surgery · 2018Trial
- Managing Opioid Withdrawal Symptoms During the Fentanyl Crisis: A Review.Substance abuse and rehabilitation · 2024Review
- Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum.Rapid communications in mass spectrometry : RCM · 2021Article
- Electroacupuncture prevents cocaine-induced conditioned place preference reinstatement and attenuates ΔFosB and GluR2 expression.Scientific reports · 2021Article
- Incidence of Postoperative Opioid Overdose and New Diagnosis of Opioid Use Disorder Among US Veterans.The American journal on addictions · 2020Article
- New directions in the treatment of opioid withdrawal.Lancet (London, England) · 2020Review
- Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016.Journal of managed care & specialty pharmacy · 2020Article
- Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial.Substance abuse : research and treatment · 2020Article
- Gabapentin prescribed during substance abuse treatment: The perspective of treatment providers.Journal of substance abuse treatment · 2019Article
- Sex Differences in Regional Brain Glucose Metabolism Following Opioid Withdrawal and Replacement.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.Drug and alcohol dependence · 2017Article
- A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.CNS drugs · 2016Article
- Gabapentin Therapy in Psychiatric Disorders: A Systematic Review.The primary care companion for CNS disorders · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
This pilot study examined the efficacy of the N-type calcium channel blocker gabapentin to improve outcomes during a brief detoxification protocol with buprenorphine. Treatment-seeking opioid-dependent individuals were enrolled in a 5-week, double-blind, placebo-controlled trial examining the effects of gabapentin during a 10-day outpatient detoxification from buprenorphine. Participants were inducted onto buprenorphine sublingual tablets during Week 1, were randomized and inducted onto gabapentin or placebo during Week 2, underwent a 10-day buprenorphine taper during Weeks 3 and 4, and then were tapered off gabapentin/placebo during Week 5. Assessments included thrice-weekly opioid withdrawal scales, vitals, and urine drug screens. Twenty-four individuals (13 male; 17 Caucasian, 3 African American, 4 Latino; mean age 29.7 years) participated in the detoxification portion of the study (gabapentin, n = 11; placebo, n = 13). Baseline characteristics did not differ significantly between groups. Self-reported and observer-rated opioid withdrawal ratings were relatively low and did not differ between groups during the buprenorphine taper. Urine results showed a Drug × Time interaction, such that the probability of opioid-positive urines significantly decreased over time in the gabapentin versus placebo groups during Weeks 3 and 4 (OR = 0.73, p = .004). These results suggest that gabapentin reduces opioid use during a 10-day buprenorphine detoxification procedure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.